FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average hurden								

hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or S	Section	on 30(h)	of the I	Investme	nt Co	mpany Act	of 194	10									
1. Name and Address of Reporting Person* Palczuk Linda					AV	2. Issuer Name <b>and</b> Ticker or Trading Symbol AVADEL PHARMACEUTICALS PLC										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner						
					AV	AVDL ]									X		er (give title			specify		
(Last) (First) (Middle) BLOCK 10-1, BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN						3. Date of Earliest Transaction (Month/Day/Year) 08/01/2018										belov	v) ¯		below)			
(Street) DUBLIN (City)			L5 Zip)		4. If	Ame	ndment	, Date o	of Origina	l Filed	d (Month/Da	ay/Yea	ar)		Individ	Form	r Joint/Group n filed by One n filed by Mor on	e Rep	orting Pers	on		
		Tabl	e I - No	n-Deriva	ative	Se	curitie	s Ac	quired,	, Dis	posed o	f, or	Ben	eficia	ally O	wne	ed					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da				Day/Year) if a		2A. Deemed Execution Date, f any Month/Day/Year)		Transaction Disposed Code (Instr. 5)		ties Acquired (A) I Of (D) (Instr. 3, 4			4 and Sec Ben Owr		curities neficially		wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v	Amount		(A) or (D)	Price	,  т	Transa	ction(s) 3 and 4)			(111511.4)		
ADSs <sup>(1)</sup> 08/0				08/01/	1/2018				A		27,900	(2)	A \$0		27,900			D				
		Та									osed of, onvertib				y Ow	ned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date,	4. Transaction Code (Instr. 8)		of		6. Date Exercisal Expiration Date (Month/Day/Year		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		str. 3	8. Pric Deriva Securi (Instr.	vative urity	9. Number of derivative Securities Beneficially Owned Following Reported Transaction( (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	or Nur of	ount nber ires								

## **Explanation of Responses:**

- 1. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value \$0.01 per share, of the issuer; ADSs may be represented by American Depositary
- 2. Represents 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant

/s/ Phillandas T. Thompson, as attorney-in-fact for Linda 08/02/2018 **Palczuk** 

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.